SSKN on NASDAQ

MELA Sciences

Strata Skin Sciences (formerly MELA Sciences, Inc.) is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations. The company's flagship product, XTRAC, is a medical device that allows for a trained dermatologist to treat skin conditions like Vitiligo and Psoriasis with monochromatic UV Light.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 19, 2026.

Overview

Jan 1, 1989Founded1

Compare with Premier Air Charter Holdings Inc., Orchestra BioMed Holdings, Inc. or Sensus Healthcare, Inc., or pick any stock.

  • TickerSSKN on NASDAQ1
  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersIrvington1
  • Websitemelasciences.com
  • Listed onNasdaq (MELA), Nasdaq (SSKN)1
  • Incorporated inDE4
  • Business address5 Walnut Grove Drive, Suite 140, Horsham, Pa 190444
  • Filer categoryNon-accelerated filer, Smaller reporting company4
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Strata Skin Sciences (formerly MELA Sciences, Inc.) is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

58.3%Gross margin5
-15.3%Operating margin5
-20.4%Net margin5
-8.5%Revenue growth, 20255
-215.3%Return on equity5
0.00×Debt to equity5
-$4.3MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue42¢$12.8M
  • Research and development1¢$421.0K
  • Other costs57¢$17.4M
  • Income tax0¢$12.0K

Out of $30.7M in revenue.5 The company lost money this year.

Financial statements

Revenue6789105$30.7M in 2025−3% since 2019
0$10.0M$20.0M$30.0M$40.0M2019: $31.6M$31.6M20192020: $23.1M$23.1M2020−27%2021: $30.0M$30.0M2021+30%2022: $36.2M$36.2M2022+21%2023: $33.4M$33.4M2023−8%2024: $33.6M$33.6M2024+1%2025: $30.7M$30.7M2025−9%
Gross profit6789105$17.9M in 2025−12% since 2019
0$10.0M$20.0M$30.0M2019: $20.3M$20.3M20192020: $14.1M$14.1M2020−30%2021: $19.9M$19.9M2021+40%2022: $21.8M$21.8M2022+10%2023: $18.5M$18.5M2023−15%2024: $19.2M$19.2M2024+4%2025: $17.9M$17.9M2025−7%
Operating income6789105-$4.7M in 2025+56% since 2019
-$10.0M-$7.5M-$5.0M-$2.5M02019: -$3.0M-$3.0M20192020: -$4.1M-$4.1M2020+35%2021: -$4.4M-$4.4M2021+8%2022: -$4.6M-$4.6M2022+6%2023: -$8.6M-$8.6M2023+85%2024: -$9.3M-$9.3M2024+8%2025: -$4.7M-$4.7M2025−49%
Net income6789105-$6.3M in 2025+65% since 2019
-$15.0M-$10.0M-$5.0M02019: -$3.8M-$3.8M20192020: -$4.4M-$4.4M2020+16%2021: -$2.7M-$2.7M2021−39%2022: -$5.5M-$5.5M2022+105%2023: -$10.8M-$10.8M2023+95%2024: -$10.1M-$10.1M2024−7%2025: -$6.3M-$6.3M2025−38%
Fiscal year2019202020212022202320242025
Revenue$31.6M6$23.1M7$30.0M8$36.2M9$33.4M10$33.6M5$30.7M5
Cost of revenue$11.3M6$9.0M7$10.1M8$14.4M9$14.9M10$14.3M5$12.8M5
Gross profit$20.3M6$14.1M7$19.9M8$21.8M9$18.5M10$19.2M5$17.9M5
Research and development$1.0M6$1.3M7$1.4M8$1.0M9$1.3M10$883.0K5$421.0K5
Selling, general and admin
Operating expenses$24.3M7$26.4M9$27.1M10$28.5M5$22.6M5
Operating income-$3.0M6-$4.1M7-$4.4M8-$4.6M9-$8.6M10-$9.3M5-$4.7M5
Interest$515.0K13$211.0K7$314.0K8$926.0K9$1.6M9
Income before tax-$2.7M8-$5.5M9-$10.9M10-$10.3M5-$6.2M5
Income tax-$149.0K6$275.0K7$34.0K8$63.0K9-$92.0K10-$170.0K5$12.0K5
Net income-$3.8M6-$4.4M7-$2.7M8-$5.5M9-$10.8M10-$10.1M5-$6.3M5
Earnings per share-$0.116-$0.136-$0.169-$3.1010-$2.655-$1.355
Earnings per share (diluted)-$0.116-$0.136-$0.169-$3.1010-$2.655-$1.355
Shares (weighted, basic)34.7M shares93.5M shares103.8M shares54.7M shares5
Shares (weighted, diluted)34.7M shares93.5M shares103.8M shares54.7M shares5

Compare MELA Sciences with another company

Leadership

Who has led MELA Sciences, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Joseph Gulfo V.2007–2013
  2. Robert Coradini2013
  3. Rosemary A. Crane2013–2014
  4. Michael R. Stewart2015–2016
  5. Frank J. McCaney2016
  6. Dolev Rafaeli2018–2021
  7. Robert Joseph Moccia2021–2023

Chair

  1. Joseph Gulfo V.2012–2013
  2. Robert Coradini2014

President

  1. Jon I. Klippel2006–2008
  2. William R. Bronner2006–2007
  3. Christiano S. Butler2006–2010
  4. Joseph Gulfo V.2007–2013
  5. Rosemary A. Crane2013–2014
  6. Michael R. Stewart2015–2016
  7. Frank J. McCaney2016
  8. Robert Joseph Moccia2021

Chief financial officer

  1. Richard I. Steinhart2006–2013
  2. Karen R. Krumeich2006
  3. Robert W. Cook2014–2015
  4. Christina L. Allgeier2015–2016
  5. Mathew C. Hill2018–2020
  6. Christopher Lesovitz2021–2023

Chief operating officer

  1. Gerald D. Wagner2006–2010
  2. Shmuel Gov2023–now
19901995200020052010201520202025
Board members and other officers (39)

Former names

  • MELA SCIENCES, INC. /NYMay 10, 2010 to Jan 4, 20164
  • ELECTRO OPTICAL SCIENCES INC /NYJun 27, 2003 to Apr 30, 20104

Timeline

  1. Mar 3, 2021New chief executive Robert Joseph Moccia becomes CEO14
  2. Apr 10, 2018New chief executive Dolev Rafaeli becomes CEO15
  3. Nov 1, 2016New chief executive Frank J. McCaney becomes CEO16
  4. Jan 5, 2016Went public Listed on NASDAQ1
  5. Dec 16, 2015New chief executive Michael R. Stewart becomes CEO17
  6. Nov 13, 2013New chief executive Rosemary A. Crane becomes CEO19
  7. Jun 24, 2013New chief executive Robert Coradini becomes CEO18
  8. Nov 14, 2007New chief executive Joseph Gulfo V. becomes CEO20
  9. Jan 1, 1989Founded Founded1

Filings

208 filings to the SEC since October 2021: 8 annual reports, 13 quarterly reports, 73 major events, 53 insider forms, 13 large holders, 1 private raises, 47 other. The latest 20:

  1. Mar 26, 202610-K EDGAR
  2. Mar 4, 2026EFFECT EDGAR
  3. Mar 4, 2026EFFECT EDGAR
  4. Mar 4, 2026EFFECT EDGAR
  5. Mar 2, 202615-12G EDGAR
  6. Feb 27, 2026POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 EDGAR
  7. Feb 27, 2026POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 EDGAR
  8. Feb 27, 2026POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 EDGAR
  9. Feb 27, 2026S-8 POS POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 EDGAR
  10. Feb 27, 2026S-8 POS POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 EDGAR
  11. Feb 27, 2026S-8 POS POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 EDGAR
  12. Feb 27, 2026S-8 POS POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 EDGAR
  13. Feb 27, 2026S-8 POS POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 EDGAR
  14. Feb 27, 2026S-8 POS POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 EDGAR
  15. Feb 27, 2026S-8 POS POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 EDGAR
  16. Feb 19, 202625 EDGAR
  17. Feb 11, 20268-K EDGAR
  18. Dec 17, 20258-K EDGAR
  19. Dec 10, 20258-K EDGAR
  20. Nov 18, 20254 EDGAR

The 208 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

15 open-market trades by officers, directors and large owners since October 2021: 13 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 18, 2025Rubinstein SamuelDirectorBuy5,000$1.41$7.0KForm 4
Nov 17, 2025Rubinstein SamuelDirectorSale14,094$1.33$18.8KForm 4
Jul 15, 2024Geiger UriDirectorBuy230,573$3.14$724.0KForm 4
Jul 15, 2024Accelmed Growth Partners (AGP) Ltd10% ownerBuy230,573$3.14$724.0KForm 4
Jul 15, 2024Rafaeli DolevChief Executive OfficerBuy19,100$3.14$60.0KForm 4
Dec 1, 2023Gov ShmuelChief Operating OfficerBuy20,000$0.45$9.0KForm 4
Nov 16, 2023Rubinstein SamuelDirectorSale1,000$0.32$320Form 4
Aug 16, 202322NW GP, Inc.10% ownerBuy1,853,056$0.55$1.0MForm 4
Aug 10, 2023Lesovitz ChristopherChief Financial OfficerBuy15,151$0.67$10.2KForm 4
Aug 10, 2023Moccia Robert JosephChief Executive OfficerBuy42,000$0.67$28.1KForm 4
Jun 15, 2022Rubinstein SamuelDirectorBuy1,050$1.04$1.1KForm 4
May 12, 2022Lesovitz ChristopherChief Financial OfficerBuy23,131$1.12$25.9KForm 4
Mar 25, 2022Humphries William D.DirectorBuy16,950$1.73$29.3KForm 4
Mar 24, 2022Humphries William D.DirectorBuy14,783$1.58$23.4KForm 4
Mar 24, 2022Moccia Robert JosephChief Executive OfficerBuy33,300$1.57$52.3KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jan 10, 2022Raised $480,212 in a private offering of equity Form D: 1 investor so far Form D

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71